Conaris Research Institute Ag

Christian-albrechts-universitat Zu Kiel

Universitatsklinikum Jena

Georg Wätzig

Dirk Seegert

Stefan Rose-John

Stefan Schreiber

Joachim Grötzinger

Nikolaus Rahaus

Jürgen Scheller

Jessica Daecke

Stephanie Tenhumberg

Matthias Laudes

Eva-Maria Theismann

Daniela Fangmann

Jörg Knipp

Karin Schwarz

Julia Keppler

Mark Ellrichmann

The present invention relates to a new pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or related compounds for beneficially influencing the intestinal microbiota and blood lipid levels. In certain embodiments, the pharmaceutical composition is partially or entirely released into the lower small intestine and/or large intestine.

Pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota

The present invention relates to a new pharmaceutical composition containing a combination of 5-aminosalicylic acid and nicotinamide or related compounds. The combination is believed to beneficially influence the intestinal microbiota and/or reduce gastrointestinal inflammation. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.

Pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation

Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala-Glu-Gly-Ala. Moreover, a pharmaceutical composition containing said dimer and various medical uses are described.

Sgp130/Fc dimers

sgp130/Fc dimers for treatment of inflammatory disease

sgp130/Fc dimers

Described are soluble gp130 polypeptide monomers and dimers, wherein, in a preferred embodiment, at least one of the three amino acid residues ThrGlnor Asnof the N-terminal Ig-like domain of gp130 is mutated to Tyr, Pheor Leu, respectively. These mutations, alone or in combination, specifically enhance binding of gp130 to its ligand complex of interleukin-6 and soluble interleukin-6 receptor, thus increasing the biological activity of the gp130 muteins. In a particularly preferred embodiment, all three mutations are combined in the triple mutein Thr102Tyr/Gln113Phe/Asn114Leu (T102Y/Q113F/N114L). Moreover, a pharmaceutical composition containing said monomers or dimers and various medical uses are described.

Soluble GP130 muteins with improved binding activity

Described are codon optimized sgp130 encoding nucleic acid molecules as well as a method for the highly efficient recombinant production of sgp130 in mammalian cells or bacteria using a nucleic acid molecule of the invention.

Optimized nucleotide sequences encoding sgp130

Growing community of inventors

Kiel, Germany

Georg Wätzig